Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
Designed to foster meaningful interprofessional and interdisciplinary collaboration, this enduring activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF). Expert faculty will also examine new and emerging CVOT data for SGLT2 inhibitors, including recent approvals and guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points, this activity includes a case-based discussion focused on key characteristics of an effective, integrated approach to HF management.
This activity is presented by Creative Educational Concepts and supported by an independent educational grant from AstraZeneca.
This activity has been planned for cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants.
Upon completion of the educational activity, participants should be able to:
- Explore the evolution of SGLT2 inhibition in the cardiovascular outcomes trial (CVOT) era and evaluate mechanisms linking type 2 diabetes (T2D) and heart failure (HF).
- Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the T2D therapeutic classes.
- Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
- Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.
PLANNER AND FACULTY DISCLOSURES
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Muthiah Vaduganathan, MD, MPH–has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.
Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Ambarish Pandey, MD, MSCS–has no relevant financial relationships to disclose in relation to the content of this activity.
Scott Urquhart, PA-C, DFAAPA–has disclosed that he is a consultant for AstraZeneca, Dexcom, Novo Nordisk. and Sanofi. He is a member of the speakers' bureau for AstraZeneca and Novo Nordisk.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-016-H01-P)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.